Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

BACKGROUND: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Ikeda, Satoshi, Kato, Terufumi, Ogura, Takashi, Sekine, Akimasa, Oda, Tsuneyuki, Masuda, Noriyuki, Igawa, Satoshi, Katono, Ken, Otani, Sakiko, Yamada, Kouzo, Saito, Haruhiro, Kondo, Tetsuro, Hosomi, Yukio, Nakahara, Yoshiro, Nishikawa, Masanori, Utumi, Keiko, Misumi, Yuki, Yamanaka, Takeharu, Sakamaki, Kentaro, Okamoto, Hiroaki
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://ncbi.nlm.nih.gov/pubmed/29499653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4150-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados